Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Viral Infections

Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir

Bone Marrow Transplantation volume 31, pages 813–816 (2003)Cite this article

Summary:

To establish the incidence of CMV viremia after allogeneic blood stem cell transplantation, we studied 51 consecutive allogeneic peripheral blood stem cell (PBSC) transplant recipients. A total of 12 recipients were at moderate risk for CMV disease and 39 were at high risk. Conditioning regimens varied, but GvHD prophylaxis consisted of tacrolimus and mini-methotrexate in all patients. All patients received prophylactic ganciclovir from admission until day −2 and prophylactic acyclovir from day −1 until day 180 after transplantation. CMV viremia was treated with ganciclovir. Using a PCR-based technique, the cumulative incidence of CMV viremia was 31±14% by day 100 and 35±14% by day 150. Donor type, CMV risk group, underlying disorder, conditioning regimen, GvHD, and steroid use were not associated with the risk for CMV viremia. No cases of CMV disease occurred. We hypothesize that the low rate of CMV viremia and the absence of CMV disease in this cohort of PBSCT transplant recipients, which contrasts with other reports, may be related to the prophylactic use of high-dose acyclovir and possibly to pretransplant use of ganciclovir.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  CAS  PubMed  Google Scholar 

  2. Bacigalupo A . Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 2002; 29: 191–195.

    Article  CAS  PubMed  Google Scholar 

  3. Storek J, Dawson MA, Storer B et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380–3389.

    Article  CAS  PubMed  Google Scholar 

  4. Ottinger HD, Beelen DW, Scheulen B et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775–2779.

    CAS  PubMed  Google Scholar 

  5. Meyers JD . Prevention and treatment of cytomegalovirus infection. Annu Rev Med 1991; 42: 179–187.

    Article  CAS  PubMed  Google Scholar 

  6. van Besien K, Devine S, Wickrema A et al. Fludarabine–melphalan is equivalent to fludarabine–thiotepa-TBI-based conditioning for allogeneic transplantation in advanced hematologic malignancies. Experience in 61 consecutive patients [abstract]. Blood 2001; 98: 788.

    Google Scholar 

  7. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.

    Article  CAS  PubMed  Google Scholar 

  8. Przepiorka D, van Besien K, Khouri I et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999; 10: 527–532.

    Article  CAS  PubMed  Google Scholar 

  9. Kapelushnik J, OR R, Slavin S, Nagler A . A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia. Bone Marrow Transplant 1997; 20: 1109–1110.

    Article  CAS  PubMed  Google Scholar 

  10. Boeckh M, Storer B, Bensinger W et al. CMV infection and disease after marrow vs PBSC transplantation: results from a randomized trial [abstract]. Blood 2001; 98 (Suppl 1): 2006.

    Google Scholar 

  11. Junghanss C, Boeckh M, Carter RA et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978–1985.

    Article  CAS  PubMed  Google Scholar 

  12. Cohen S, Fung H, Spielberger R et al. Cytomegalovirus infection and disease in non-myeloablative allogeneic hematopoietic stem cell transplant patients [abstract]. ASCO Proc 2002; 21: 1661.

    Google Scholar 

  13. Ljungman P, de la CR, Milpied N et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99: 3050–3056.

    Article  CAS  PubMed  Google Scholar 

  14. Reusser P, Einsele H, Lee J et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159–1164.

    Article  CAS  PubMed  Google Scholar 

  15. Nakamura R, Cortez K, Solomon S et al. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 235–242.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Atkinson K, Downs K, Golenia M et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: Absence of clinical cytomegalovirus infection. Brit J Haematol 1991; 79: 57–62.

    Article  CAS  Google Scholar 

  17. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Int Med 1993; 118: 179–184.

    Article  CAS  PubMed  Google Scholar 

  18. Limaye AP, Bowden RA, Myerson D, Boeckh M . Cytomegalovirus disease occurring before engraftment in marrow transplant recipients. Clin Infect Dis 1997; 24: 830–835.

    Article  CAS  PubMed  Google Scholar 

  19. Meyers JD, Reed EC, Shepp DH et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70–75.

    Article  CAS  PubMed  Google Scholar 

  20. Prentice HG, Gluckman E, Powles RL et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. Bone Marrow Transplant 1997; 19: 129–133.

    Article  CAS  PubMed  Google Scholar 

  21. De la Cámara R, Fernandez-Ranada JM . Does high-dose prophylactic acyclovir add benefit in allogeneic marrow transplant recipients receiving prophylactic or preemptive ganciclovir? J Infect Dis 1999; 180: 571–574.

    Article  PubMed  Google Scholar 

  22. Boeckh M, Gooley TA, Bowden RA . Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. J Infect Dis 1998; 178: 1153–1157.

    Article  CAS  PubMed  Google Scholar 

  23. Talarico CL, Burnette TC, Miller WH et al. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother 1999; 43: 1941–1946.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gluckman E, Lotsberg J, Devergie A et al. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet 1983; 2: 706–708.

    Article  CAS  PubMed  Google Scholar 

  25. Costa S, Anaissie E, Badros A et al. High incidence of CMV reactivation without disease following mini-allograft peripheral stem cell transplantation [abstract]. Blood 2000; 96 (Suppl 1): 5206.

    Google Scholar 

  26. Qamruddin AO, Oppenheim BA, Guiver M et al. Screening for CMV infection in allogeneic bone marrow transplant recipients using quantitative whole blood PCR method. Bone Marrow Transplant 2001; 27: 301–306.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, Chicago, USA

    A Verma, S Devine, M Morrow, Y-H Chen, D Peace, W Stock, K Pursell, A Wickrema, M Yassine, E Jessop & K van Besien

  2. Department of Pathology, Section of Hematology/Oncology, University of Illinois at Chicago, Chicago, USA

    M Mihalov

Authors
  1. A Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Devine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Morrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y-H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Mihalov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Peace
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Stock
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Pursell
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Wickrema
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Yassine
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E Jessop
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K van Besien
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verma, A., Devine, S., Morrow, M. et al. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant 31, 813–816 (2003). https://doi.org/10.1038/sj.bmt.1703916

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703916

Keywords

Search

Advanced search

Quick links